Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ATXI, Q2 2026
No superinvestor reported holding ATXI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Avenue Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 3, 2024 (view filing) | Dec 2 | 1 day | Herskowitz NeilDirector | SSaleCOMMON STOCK, PAR VALUE $0.0001 | −23 | $2.00 | −$46 | −19.2%97 after | |
| Nov 7, 2024 (view filing) | Nov 5 | 2 days | Kranzler Jay DDirector | SSaleCOMMON STOCK, PAR VALUE $0.0001 | −61 | $2.24 | −$136.64 | −9.8%559 after | |
| Oct 1, 2024 (view filing) | Sep 27-30 | 4 days | Kranzler Jay DDirector | PPurchaseCOMMON STOCK, PAR VALUE $0.0001 | +500 | $2.50 | +$1.25K | +416.7%620 after | 2 lots |
| Dec 13, 2023 (view filing)4:02 PM ET | Dec 11 | 2 days | Davidow Robert L10% Owner | SSale | −264.0K | $0.14 | −$37.0K | −27.9%681.0K after | |
| Dec 13, 2023 (view filing)4:02 PM ET | Dec 11 | 2 days | Davidow Robert L10% Owner | SSale | −353.0K | $0.1405 | −$49.6K | −81.5%80.0K after | 5 lots |
| Sep 12, 2023 (view filing) | Sep 8 | 4 days | Rosenwald Lindsay A MDDirector | PPurchase | +348.7K | $0.72 | +$251.0K | +6,178.9%354.3K after | |
| Sep 12, 2023 (view filing) | Sep 8 | 4 days | Fortress Biotech, Inc.10% Owner | PPurchase | +418.4K | $0.72 | +$301.3K | +68.1%1.03M after | |
| Oct 13, 2022 (view filing) | Oct 11 | 2 days | InvaGen Pharmaceuticals, Inc.10% Owner | SSaleCommon Stock, par value $0.0001 per share | −388.9K | $7.71 | −$3.00M | −100.0%0 after | |
| Sep 15, 2021 (view filing) | Sep 15 | Same day | Vazzano Joseph WalterChief Financial Officer | SSale | −7.16K | $1.62 | −$11.6K | −9.9%65.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Avenue Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding ATXI in 13F filings for Q2 2026.